Histoplasmosis Treatment Market size is expected to reach USD 62 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of histoplasmosis treatment was over USD 2 billion. The growth of the market can be attributed to the increasing incidences of histoplasmosis, especially amongst a few specific occupational groups. It is very common in construction workers, poultry farmers, and people with weakened immune systems. A study calculated the incidence of histoplasmosis in U.S. adults 65 years old and older at 3.4 cases for every 100,000 population.
Histoplasmosis is a relatively uncommon disease, so it can be tough to diagnose. However, as awareness of the disease increases, healthcare professionals are more likely to consider it as a potential diagnosis that can lead to earlier and more effective treatment. Therefore, growing awareness about histoplasmosis treatment among healthcare professionals as well as the population is expected to boost the market growth in the projected period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~9% |
|
Base Year Market Size (2023) |
~USD 2 billion |
|
Forecast Year Market Size (2036) |
~USD 62 billion |
|
Regional Scope |
|
Type (Acute, Chronic)
Based on type, the acute segment in the histoplasmosis treatment market is anticipated to garner the largest share of 60% during the projected period. The growth of this market can be attributed to the high prevalence and easy transmission of the disease. Acute histoplasmosis is more common, which is estimated to boost the segment growth. Acute histoplasmosis is more common than chronic histoplasmosis and it is estimated that 80% of cases are acute. Furthermore, acute histoplasmosis can be easily transmitted via the inhalation of spores from infected bats or bird droppings. This ease of transmission contributes to the high incidence of this disease. Therefore, it is predicted to drive the segment growth which further might boost the market in the projected time period.
Drug Type (Ketoconazole, Amphotericin B, Itraconazole)
In terms of drug type, the amphotericin B segment is predicted to dominate the global histoplasmosis treatment market by the end of 2036. This increase can be explained by the higher use of amphotericin B for histoplasmosis treatment. The drug is recommended for pregnant women with histoplasmosis demanding immediate treatment. It is also used to treat acute progressive disseminated histoplasmosis as maintenance therapy, which in turn drives up the growth of this segment.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Diagnosis |
|
|
Drug Type |
|
|
Route of Administration |
|
North American Market Forecasts
The histoplasmosis treatment market in the North America region is anticipated to gain the largest revenue share of 33% throughout the projected period. The United States is considered to be the dominant country in terms of disease growth rate and is set to be the country to expand the histoplasmosis treatment market the most. This is due to the increasing number of patients with malignant diseases and immunodeficiency. According to the CDC, in North America histoplasmosis is the most common disease in HIV/AIDS patients, of which 4,444 and 30% of patients die due to their immunocompromised state. Additionally, an increasing research and development and technological advancements in the region are some of the driving forces for the histoplasmosis treatment market.
European Market Statistics
The histoplasmosis treatment market in the Europe region is anticipated to hold substantial growth in the time period between 2024-2036. Increasing focus on medical facilities and increasing population aged 65 and above are expected to drive market growth. Furthermore, the demand for the histoplasmosis treatment market is increasing due to the rise in chronic diseases that weaken the human immunity of people in the region. Furthermore, the European Union also offers support for the advancement of healthcare infrastructure and improving the healthcare industry in Europe. They consecutively offer funds for the research and development of novel therapies in order to offer enhanced histoplasmosis treatment to patients in this region.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?